KEN MENDOZA

Danger Theory–inspired innovator Ken Mendoza operates at the intersection of deep biomedical science, scalable software architecture, and a 19-asset intellectual property portfolio. His journey began in the trenches of Silicon Valley tech companies, where he learned to build scalable systems and navigate the complex path from innovation to IPO. His technical foundation spans 25+ years of AI and software development, including leadership roles that culminated in a successful NASDAQ public offering.

The defining moment came during a deeply personal health crisis experienced by Ken's soulmate and the love of his life, Toni. Her medical journey—a relentless series of more than a hundred complex tests involving numerous specialists—ultimately led to the diagnoses of both a brain tumor and autoimmune disease, conditions that had previously gone undetected. This transformative experience exposed fundamental gaps in medical information management and care coordination, inspiring Ken's mission to revolutionize healthcare through AI and fueling the creation of MedAdvocate.

Today, Ken operates at the unique intersection of deep biomedical science, scalable software architecture, and defensible intellectual property backed by a 19-asset intellectual property portfolio. Ken's work develops Danger Theory–inspired computational frameworks that detect danger signals in immune, physical, and AI systems. His research spans from Danger Theory–inspired computational models of immune danger signals and tissue stress to building AI-powered clinical tools.

With 14 patents in proteomics and 5 additional provisional patents spanning quantum computing, AI, materials science, and other domains, plus extensive experience in drug target identification, Ken brings a rare combination of scientific rigor, technical execution, and venture leadership to the next generation of healthcare innovation.